Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells".

Journal of virology

Devhare PB, Sasaki R, Shrivastava S, Di Bisceglie AM, Ray R, Ray RB.
PMID: 28455354
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00349-17. Print 2017 May 15.

No abstract available.

Cite
Devhare PB, Sasaki R, Shrivastava S, et al. Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells". J Virol. 2017;91(10)doi: 10.1128/JVI.00349-17.
Devhare, P. B., Sasaki, R., Shrivastava, S., Di Bisceglie, A. M., Ray, R., & Ray, R. B. (2017). Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells". Journal of virology, 91(10), . https://doi.org/10.1128/JVI.00349-17
Devhare, Pradip B, et al. "Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells"." Journal of virology vol. 91,10 (2017). doi: https://doi.org/10.1128/JVI.00349-17
Devhare PB, Sasaki R, Shrivastava S, Di Bisceglie AM, Ray R, Ray RB. Correction for Devhare et al., "Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells". J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.00349-17. Print 2017 May 15. PMID: 28455354; PMCID: PMC5411579.
Copy Download .nbib Format: NLM
The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma.

Infectious disease clinics of North America

Hayashi PH, Di Bisceglie AM.
PMID: 16527646
Infect Dis Clin North Am. 2006 Mar;20(1):1-25. doi: 10.1016/j.idc.2006.01.003.

Much information has been gained in the diagnosis and treatment of HCC during the last 15 years. Ever improving imaging technology has made nonhistologic diagnostic criteria possible, albeit controversial. Liver transplantation, resection, and RFA are considered curative options. Yet,HCC...

Cite
Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect Dis Clin North Am. 2006;20(1):1-25doi: 10.1016/j.idc.2006.01.003.
Hayashi, P. H., & Di Bisceglie, A. M. (2006). The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infectious disease clinics of North America, 20(1), 1-25. https://doi.org/10.1016/j.idc.2006.01.003
Hayashi, Paul H, and Di Bisceglie, Adrian M. "The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma." Infectious disease clinics of North America vol. 20,1 (2006): 1-25. doi: https://doi.org/10.1016/j.idc.2006.01.003
Hayashi PH, Di Bisceglie AM. The progression of hepatitis B- and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma. Infect Dis Clin North Am. 2006 Mar;20(1):1-25. doi: 10.1016/j.idc.2006.01.003. PMID: 16527646.
Copy Download .nbib Format: NLM
Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.

Genome medicine

Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM.
PMID: 21345258
Genome Med. 2011 Feb 08;3(2):8. doi: 10.1186/gm222.

Chronic hepatitis C virus (HCV) infection is a major cause of liver disease worldwide. HCV infection is currently treated with IFNα plus ribavirin for 24 to 48 weeks. This demanding therapy fails in up to 50% of patients, so...

Cite
Tavis JE, Donlin MJ, Aurora R, et al. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. Genome Med. 2011;3(2):8doi: 10.1186/gm222.
Tavis, J. E., Donlin, M. J., Aurora, R., Fan, X., & Di Bisceglie, A. M. (2011). Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. Genome medicine, 3(2), 8. https://doi.org/10.1186/gm222
Tavis, John E, et al. "Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics." Genome medicine vol. 3,2 (2011): 8. doi: https://doi.org/10.1186/gm222
Tavis JE, Donlin MJ, Aurora R, Fan X, Di Bisceglie AM. Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics. Genome Med. 2011 Feb 08;3(2):8. doi: 10.1186/gm222. PMID: 21345258; PMCID: PMC3092093.
Copy Download .nbib Format: NLM
Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis.

Hepatology communications

Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, Hassan MA, Darling JM, Feld JJ, Akushevich L, Vainorius M, Nelson DR, Fried MW, Brown RS, Terrault NA.
PMID: 31592494
Hepatol Commun. 2019 Aug 07;3(10):1388-1399. doi: 10.1002/hep4.1412. eCollection 2019 Oct.

Recent studies have suggested a negative impact of hepatocellular carcinoma (HCC) on sustained virologic response (SVR) to hepatitis C virus (HCV) direct acting antivirals (DAAs). We compared the effectiveness of DAAs in patients with cirrhosis, with and without HCC,...

Cite
Radhakrishnan K, Di Bisceglie AM, Reddy KR, et al. Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. Hepatol Commun. 2019;3(10):1388-1399doi: 10.1002/hep4.1412.
Radhakrishnan, K., Di Bisceglie, A. M., Reddy, K. R., Lim, J. K., Levitsky, J., Hassan, M. A., Darling, J. M., Feld, J. J., Akushevich, L., Vainorius, M., Nelson, D. R., Fried, M. W., Brown, R. S., & Terrault, N. A. (2019). Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. Hepatology communications, 3(10), 1388-1399. https://doi.org/10.1002/hep4.1412
Radhakrishnan, Kavita, et al. "Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis." Hepatology communications vol. 3,10 (2019): 1388-1399. doi: https://doi.org/10.1002/hep4.1412
Radhakrishnan K, Di Bisceglie AM, Reddy KR, Lim JK, Levitsky J, Hassan MA, Darling JM, Feld JJ, Akushevich L, Vainorius M, Nelson DR, Fried MW, Brown RS, Terrault NA. Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. Hepatol Commun. 2019 Aug 07;3(10):1388-1399. doi: 10.1002/hep4.1412. eCollection 2019 Oct. PMID: 31592494; PMCID: PMC6771159.
Copy Download .nbib Format: NLM
Michael Charles Kew - Frontrunner in Hepatology.

Journal of hepatology

Kassianides C, Dusheiko G, Di Bisceglie A, Hoofnagle JH.
PMID: 34887100
J Hepatol. 2021 Dec 06; doi: 10.1016/j.jhep.2021.11.019. Epub 2021 Dec 06.

No abstract available.

Cite
Kassianides C, Dusheiko G, Di Bisceglie A, et al. Michael Charles Kew - Frontrunner in Hepatology. J Hepatol. 2021;doi: 10.1016/j.jhep.2021.11.019.
Kassianides, C., Dusheiko, G., Di Bisceglie, A., & Hoofnagle, J. H. (2021). Michael Charles Kew - Frontrunner in Hepatology. Journal of hepatology, . https://doi.org/10.1016/j.jhep.2021.11.019
Kassianides, Chris, et al. "Michael Charles Kew - Frontrunner in Hepatology." Journal of hepatology vol. (2021). doi: https://doi.org/10.1016/j.jhep.2021.11.019
Kassianides C, Dusheiko G, Di Bisceglie A, Hoofnagle JH. Michael Charles Kew - Frontrunner in Hepatology. J Hepatol. 2021 Dec 06; doi: 10.1016/j.jhep.2021.11.019. Epub 2021 Dec 06. PMID: 34887100.
Copy Download .nbib Format: NLM
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.

Hepatology (Baltimore, Md.)

Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, Khalili M, Fontana RJ, Sterling RK, Terrault N, Feld JJ, Di Bisceglie AM, Lau DTY, Hassan M, Janssen HLA.
PMID: 32936969
Hepatology. 2021 Jun;73(6):2124-2140. doi: 10.1002/hep.31554. Epub 2021 May 21.

BACKGROUND AND AIMS: Outcomes of persons with chronic hepatitis B virus (HBV) infection in the era of antiviral therapy (AVT) are not well characterized. We determined the incidence and factors associated with clinical outcomes in a multiethnic, North American...

Cite
Lok AS, Perrillo R, Lalama CM, et al. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology. 2021;73(6):2124-2140doi: 10.1002/hep.31554.
Lok, A. S., Perrillo, R., Lalama, C. M., Fried, M. W., Belle, S. H., Ghany, M. G., Khalili, M., Fontana, R. J., Sterling, R. K., Terrault, N., Feld, J. J., Di Bisceglie, A. M., Lau, D. T. Y., Hassan, M., Janssen, H. L. A. (2021). Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology (Baltimore, Md.), 73(6), 2124-2140. https://doi.org/10.1002/hep.31554
Lok, Anna S, et al. "Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy." Hepatology (Baltimore, Md.) vol. 73,6 (2021): 2124-2140. doi: https://doi.org/10.1002/hep.31554
Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, Khalili M, Fontana RJ, Sterling RK, Terrault N, Feld JJ, Di Bisceglie AM, Lau DTY, Hassan M, Janssen HLA. Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology. 2021 Jun;73(6):2124-2140. doi: 10.1002/hep.31554. Epub 2021 May 21. PMID: 32936969; PMCID: PMC8546406.
Copy Download .nbib Format: NLM
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.

Drug safety

Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N.
PMID: 33141341
Drug Saf. 2021 Feb;44(2):133-165. doi: 10.1007/s40264-020-01014-2. Epub 2020 Nov 03.

With the widespread development of new drugs to treat chronic liver diseases (CLDs), including viral hepatitis and nonalcoholic steatohepatitis (NASH), more patients are entering trials with abnormal baseline liver tests and with advanced liver injury, including cirrhosis. The current...

Cite
Treem WR, Palmer M, Lonjon-Domanec I, et al. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf. 2020;44(2):133-165doi: 10.1007/s40264-020-01014-2.
Treem, W. R., Palmer, M., Lonjon-Domanec, I., Seekins, D., Dimick-Santos, L., Avigan, M. I., Marcinak, J. F., Dash, A., Regev, A., Maller, E., Patwardhan, M., Lewis, J. H., Rockey, D. C., Di Bisceglie, A. M., Freston, J. W., Andrade, R. J., & Chalasani, N. (2021). Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug safety, 44(2), 133-165. https://doi.org/10.1007/s40264-020-01014-2
Treem, William R, et al. "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis." Drug safety vol. 44,2 (2021): 133-165. doi: https://doi.org/10.1007/s40264-020-01014-2
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf. 2021 Feb;44(2):133-165. doi: 10.1007/s40264-020-01014-2. Epub 2020 Nov 03. PMID: 33141341; PMCID: PMC7847464.
Copy Download .nbib Format: NLM
Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites.

Cureus

Stotts MJ, Cheung A, Hammami MB, Westrich DJ, Anderson E, Counts L, Befeler AS, Di Bisceglie AM, Prather C.
PMID: 34249551
Cureus. 2021 Jun 02;13(6):e15403. doi: 10.7759/cureus.15403. eCollection 2021 Jun.

Background Bacterial translocation plays a pivotal role in the natural course of cirrhosis and its complications. Serum-derived bovine immunoglobulin (SBI) is an oral medical food that has been shown to both reduce inflammation in the intestines and neutralize bacteria....

Cite
Stotts MJ, Cheung A, Hammami MB, et al. Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites. Cureus. 2021;13(6):e15403doi: 10.7759/cureus.15403.
Stotts, M. J., Cheung, A., Hammami, M. B., Westrich, D. J., Anderson, E., Counts, L., Befeler, A. S., Di Bisceglie, A. M., & Prather, C. (2021). Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites. Cureus, 13(6), e15403. https://doi.org/10.7759/cureus.15403
Stotts, Matthew J, et al. "Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites." Cureus vol. 13,6 (2021): e15403. doi: https://doi.org/10.7759/cureus.15403
Stotts MJ, Cheung A, Hammami MB, Westrich DJ, Anderson E, Counts L, Befeler AS, Di Bisceglie AM, Prather C. Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites. Cureus. 2021 Jun 02;13(6):e15403. doi: 10.7759/cureus.15403. eCollection 2021 Jun. PMID: 34249551; PMCID: PMC8253499.
Copy Download .nbib Format: NLM
Evaluation of the friction of self-ligating and conventional bracket systems.

European journal of dentistry

Tecco S, Di Iorio D, Nucera R, Di Bisceglie B, Cordasco G, Festa F.
PMID: 21769273
Eur J Dent. 2011 Jul;5(3):310-7.

OBJECTIVES: This in vitro study evaluated the friction (F) generated by aligned stainless steel (SS) conventional brackets, self-ligating Damon MX(©) brackets (SDS Ormco, Glendora, California, USA), Time3(©) brackets (American Orthodontics, Sheboygan, Wisconsin, USA), Vision LP(©) brackets (American Orthodontics), and...

Cite
Tecco S, Di Iorio D, Nucera R, et al. Evaluation of the friction of self-ligating and conventional bracket systems. Eur J Dent. 2011;5(3):310-7
Tecco, S., Di Iorio, D., Nucera, R., Di Bisceglie, B., Cordasco, G., & Festa, F. (2011). Evaluation of the friction of self-ligating and conventional bracket systems. European journal of dentistry, 5(3), 310-7.
Tecco, Simona, et al. "Evaluation of the friction of self-ligating and conventional bracket systems." European journal of dentistry vol. 5,3 (2011): 310-7.
Tecco S, Di Iorio D, Nucera R, Di Bisceglie B, Cordasco G, Festa F. Evaluation of the friction of self-ligating and conventional bracket systems. Eur J Dent. 2011 Jul;5(3):310-7. PMID: 21769273; PMCID: PMC3137445.
Copy Download .nbib Format: NLM
The AASLD and public policy: coming in out of the cold.

Hepatology (Baltimore, Md.)

Di Bisceglie AM.
PMID: 17538960
Hepatology. 2007 Jun;45(6):1335-6. doi: 10.1002/hep.21772.

No abstract available.

Cite
Di Bisceglie AM. The AASLD and public policy: coming in out of the cold. Hepatology. 2007;45(6):1335-6doi: 10.1002/hep.21772.
Di Bisceglie, A. M. (2007). The AASLD and public policy: coming in out of the cold. Hepatology (Baltimore, Md.), 45(6), 1335-6. https://doi.org/10.1002/hep.21772
Di Bisceglie, Adrian M. "The AASLD and public policy: coming in out of the cold." Hepatology (Baltimore, Md.) vol. 45,6 (2007): 1335-6. doi: https://doi.org/10.1002/hep.21772
Di Bisceglie AM. The AASLD and public policy: coming in out of the cold. Hepatology. 2007 Jun;45(6):1335-6. doi: 10.1002/hep.21772. PMID: 17538960.
Copy Download .nbib Format: NLM
Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA.

Hepatology research : the official journal of the Japan Society of Hepatology

Di Bisceglie AM, Befeler AS.
PMID: 17877490
Hepatol Res. 2007 Sep;37:S251-3. doi: 10.1111/j.1872-034X.2007.00192.x.

It is now apparent that hepatocellular carcinoma is occurring with increasing frequency in the USA. This mirrors a trend that occurred in Japan approximately 10 years earlier. Although the approach to diagnosis and treatment are similar in Japan and...

Cite
Di Bisceglie AM, Befeler AS. Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. Hepatol Res. 2007;37:S251-3doi: 10.1111/j.1872-034X.2007.00192.x.
Di Bisceglie, A. M., & Befeler, A. S. (2007). Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. Hepatology research : the official journal of the Japan Society of Hepatology, 37S251-3. https://doi.org/10.1111/j.1872-034X.2007.00192.x
Di Bisceglie, Adrian M, and Befeler, Alex S. "Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA." Hepatology research : the official journal of the Japan Society of Hepatology vol. 37 (2007): S251-3. doi: https://doi.org/10.1111/j.1872-034X.2007.00192.x
Di Bisceglie AM, Befeler AS. Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. Hepatol Res. 2007 Sep;37:S251-3. doi: 10.1111/j.1872-034X.2007.00192.x. PMID: 17877490.
Copy Download .nbib Format: NLM
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.

Hepatology (Baltimore, Md.)

Sulkowski MS, Moon JS, Sherman KE, Morelli G, Darling JM, Muir AJ, Khalili M, Fishbein DA, Hinestrosa F, Shiffman ML, Di Bisceglie A, Rajender Reddy K, Pearlman B, Lok AS, Fried MW, Stewart PW, Peter J, Wadsworth S, Kixmiller S, Sloan A, Vainorius M, Horne PM, Michael L, Dong M, Evon DM, Segal JB, Nelson DR.
PMID: 34255381
Hepatology. 2021 Dec;74(6):2952-2964. doi: 10.1002/hep.32053. Epub 2021 Aug 26.

BACKGROUND AND AIMS: Multiple direct-acting antiviral (DAA) regimens are available to treat HCV genotype 1 infection. However, comparative effectiveness from randomized controlled trials of DAA regimens is unavailable.APPROACH AND RESULTS: We conducted a pragmatic randomized controlled trial (NCT02786537) to...

Cite
Sulkowski MS, Moon JS, Sherman KE, et al. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021;74(6):2952-2964doi: 10.1002/hep.32053.
Sulkowski, M. S., Moon, J. S., Sherman, K. E., Morelli, G., Darling, J. M., Muir, A. J., Khalili, M., Fishbein, D. A., Hinestrosa, F., Shiffman, M. L., Di Bisceglie, A., Rajender Reddy, K., Pearlman, B., Lok, A. S., Fried, M. W., Stewart, P. W., Peter, J., Wadsworth, S., Kixmiller, S., Sloan, A., Vainorius, M., Horne, P. M., Michael, L., Dong, M., Evon, D. M., Segal, J. B., Nelson, D. R. (2021). A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology (Baltimore, Md.), 74(6), 2952-2964. https://doi.org/10.1002/hep.32053
Sulkowski, Mark S, et al. "A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study." Hepatology (Baltimore, Md.) vol. 74,6 (2021): 2952-2964. doi: https://doi.org/10.1002/hep.32053
Sulkowski MS, Moon JS, Sherman KE, Morelli G, Darling JM, Muir AJ, Khalili M, Fishbein DA, Hinestrosa F, Shiffman ML, Di Bisceglie A, Rajender Reddy K, Pearlman B, Lok AS, Fried MW, Stewart PW, Peter J, Wadsworth S, Kixmiller S, Sloan A, Vainorius M, Horne PM, Michael L, Dong M, Evon DM, Segal JB, Nelson DR. A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. Hepatology. 2021 Dec;74(6):2952-2964. doi: 10.1002/hep.32053. Epub 2021 Aug 26. PMID: 34255381; PMCID: PMC8639765.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries